Pancreatic cancer natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The symptoms of pancreatic cancer usually develop in the sixth decade of life, and start with symptoms such as [[jaundice]], light-colored stools, dark urine, pain in the upper or middle [[abdomen]] and back, unexplained [[weight loss]], anorexia and [[fatigue]].Symptoms typically develop about 20-30 years after exposure to risk factors such as smoking and alcohol. Genetic factors such as alterations in tumor suppressor genes, oncogenes and different signaling pathways are responsible. If left untreated, patients with pancreatic cancer may progress to develop exocrine pancreatic insufficiency arising from pancreatic duct obstruction leading to malabsorption, malnutrition and cachexia. Dudodenal obstruction and biliary obstruction may cause symptoms of bowel obstruction and jaundice.Common complications of pancreatic cancer may arise as a result of the disease or therapy (surgical or medical). Depending on the extent of the tumor at the time of diagnosis, the prognosis is generally regarded as poor, with complete [[remission (medicine)|remission]] extremely rare. | The symptoms of [[pancreatic cancer]] usually develop in the sixth decade of life, and start with symptoms such as [[jaundice]], [[Acholic stools|light-colored stools]], [[Urine|dark urine]], pain in the upper or middle [[abdomen]] and back, unexplained [[weight loss]], anorexia and [[fatigue]].Symptoms typically develop about 20-30 years after exposure to risk factors such as [[smoking]] and [[alcohol]]. Genetic factors such as alterations in [[Tumor suppressor gene|tumor suppressor genes]], [[Oncogene|oncogenes]] and different signaling pathways are responsible. If left untreated, patients with [[pancreatic cancer]] may progress to develop [[Exocrine gland|exocrine]] [[pancreatic insufficiency]] arising from [[pancreatic duct]] [[obstruction]] leading to [[malabsorption]], [[malnutrition]] and [[cachexia]]. Dudodenal [[obstruction]] and [[Bile duct|biliary]] [[obstruction]] may cause symptoms of [[bowel obstruction]] and [[jaundice]]. Common complications of [[pancreatic cancer]] may arise as a result of the [[disease]] or [[therapy]] (surgical or [[Medicine|medical]]). Depending on the extent of the tumor at the time of diagnosis, the prognosis is generally regarded as poor, with complete [[remission (medicine)|remission]] extremely rare. | ||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
===Natural History=== | ===Natural History=== | ||
*The symptoms of pancreatic cancer usually develop in the sixth decade of life, and start with symptoms such as [[jaundice]], light-colored stools, dark urine, pain in the upper or middle [[abdomen]] and back, unexplained [[weight loss]], anorexia and [[fatigue]]. | *The symptoms of [[pancreatic cancer]] usually develop in the sixth decade of life, and start with symptoms such as [[jaundice]], light-colored stools, [[Urine|dark urine]], pain in the upper or middle [[abdomen]] and back, unexplained [[weight loss]], [[anorexia]] and [[fatigue]]. | ||
*The symptoms of pancreatic cancer typically develop about 20-30 years after exposure to risk factors such as smoking and alcohol. Genetic factors such as alterations in tumor suppressor genes, oncogenes and different signaling pathways may also be responsible. | *The symptoms of [[pancreatic cancer]] typically develop about 20-30 years after exposure to risk factors such as [[smoking]] and [[alcohol]]. Genetic factors such as alterations in [[Tumor suppressor gene|tumor suppressor genes]], [[Oncogene|oncogenes]] and different [[Signal transduction|signaling pathways]] may also be responsible. | ||
*If left untreated, patients with pancreatic cancer may progress to develop exocrine pancreatic insufficiency arising from pancreatic duct obstruction leading to malabsorption, malnutrition and cachexia. Dudodenal obstruction and biliary obstruction may cause symptoms of bowel obstruction and jaundice. | *If left untreated, patients with [[pancreatic cancer]] may progress to develop [[Exocrine gland|exocrine]] [[pancreatic insufficiency]] arising from [[pancreatic duct]] [[obstruction]] leading to [[malabsorption]], [[malnutrition]] and [[cachexia]]. Dudodenal [[obstruction]] and [[Bile duct|biliary]] [[obstruction]] may cause symptoms of [[Intestine|bowel]] [[obstruction]] and [[jaundice]]. | ||
===Complications=== | ===Complications=== | ||
*Common complications of pancreatic cancer may arise as a result of the disease or therapy: | *Common complications of [[pancreatic cancer]] may arise as a result of the [[disease]] or [[therapy]]: | ||
==== Malabsorption: ==== | ==== Malabsorption: ==== | ||
*[[Pancreatic insufficiency|Exocrine pancreatic insufficiency]] due to [[pancreatic duct]] [[obstruction]] by the [[tumor]] may lead to [[malabsorption]]. [[Malabsorption]] in patients presents with [[anorexia]], [[weight loss]], and [[diarrhea]]. | *[[Pancreatic insufficiency|Exocrine pancreatic insufficiency]] due to [[pancreatic duct]] [[obstruction]] by the [[tumor]] may lead to [[malabsorption]]. [[Malabsorption]] in patients presents with [[anorexia]], [[weight loss]], and [[diarrhea]]. | ||
*Patients with advanced pancreatic cancer may develop intractable pain requiring narcotic analgesics and surgical intervention such as neurolysis of | ==== Pain: ==== | ||
*Patients with advanced [[pancreatic cancer]] may develop intractable pain requiring [[Narcotic|narcotic analgesics]] and surgical [[Intervention (counseling)|intervention]] such as [[neurolysis]] of [[celiac ganglia]]. | |||
====Jaundice:==== | ====Jaundice:==== | ||
*[[Jaundice|Obstructive jaundice]] can present with features of [[cholangitis]]: | *[[Jaundice|Obstructive jaundice]] can present with features of [[cholangitis]]: | ||
| Line 30: | Line 31: | ||
**[[Abdominal pain|Right upper quadrant pain]] | **[[Abdominal pain|Right upper quadrant pain]] | ||
**[[Anorexia]] | **[[Anorexia]] | ||
*Patients may require [[Endoscopy|Endoscopic]] [[decompression]] with [[stent]] placement in patients due to biliary obstruction. | *Patients may require [[Endoscopy|Endoscopic]] [[decompression]] with [[stent]] placement in patients due to [[Cholestasis|biliary obstruction]]. | ||
====Duodenal obstruction==== | ====Duodenal obstruction==== | ||
*Patients may develop duodenal obstruction as a result of complications of surgery. | *Patients may develop [[Duodenum|duodenal]] [[obstruction]] as a result of complications of [[surgery]]. | ||
*Duodenal obstruction may be treated with [[Endoscopy|endoscopic]] [[Stent|stenting]] or [[gastrojejunostomy]]. | *[[Duodenum|Duodenal]] [[obstruction]] may be treated with [[Endoscopy|endoscopic]] [[Stent|stenting]] or [[gastrojejunostomy]]. | ||
===Prognosis=== | ===Prognosis=== | ||
*The primary factors that influence prognosis are: | *The primary factors that influence [[prognosis]] are: | ||
:*Whether the tumor is localized and can be completely resected | :*Whether the tumor is localized and can be completely resected | ||
:*Whether the tumor has spread to lymph nodes or elsewhere | :*Whether the tumor has spread to lymph nodes or elsewhere | ||
| Line 96: | Line 97: | ||
===5-Year Survival=== | ===5-Year Survival=== | ||
*For patients with localized disease and small cancers (<2 cm) with no lymph node metastases and no extension beyond the capsule of the pancreas, complete surgical resection is associated with a 5-year survival rate of 18% to 24%. | *For patients with localized disease and small cancers (<2 cm) with no lymph node metastases and no extension beyond the capsule of the [[pancreas]], complete [[Resection|surgical resection]] is associated with a 5-year survival rate of 18% to 24%. | ||
* Between 2007 and 2010, the 5-year relative survival of patients with pancreatic cancer was 7.2%.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | * Between 2007 and 2010, the 5-year relative survival of patients with pancreatic cancer was 7.2%.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
| Line 102: | Line 103: | ||
* When stratified by age, the 5-year relative survival of patients with pancreatic cancer was 10% and 4.6% for patients <65 and ≥ 65 years of age respectively.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | * When stratified by age, the 5-year relative survival of patients with pancreatic cancer was 10% and 4.6% for patients <65 and ≥ 65 years of age respectively.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
* The survival of patients with pancreatic cancer varies with the stage of the disease. Shown below is a table depicting the 5-year relative survival by the stage of pancreatic cancer:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref><ref name="Ghaneh">{{cite journal |author=Ghaneh P, Costello E, Neoptolemos JP |title=Biology and management of pancreatic cancer |journal=Gut |volume=56 |issue=8 |pages=1134-52 |year=2007 |pmid=17625148 |doi=10.1136/gut.2006.103333}}</ref> | * The survival of patients with [[pancreatic cancer]] varies with the stage of the disease. Shown below is a table depicting the 5-year relative survival by the stage of pancreatic cancer:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref><ref name="Ghaneh">{{cite journal |author=Ghaneh P, Costello E, Neoptolemos JP |title=Biology and management of pancreatic cancer |journal=Gut |volume=56 |issue=8 |pages=1134-52 |year=2007 |pmid=17625148 |doi=10.1136/gut.2006.103333}}</ref> | ||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | {| style="cellpadding=0; cellspacing= 0; width: 600px;" | ||
| Line 121: | Line 122: | ||
Shown below is an image depicting the 5-year conditional relative survival (probability of surviving in the next 5-years given the cohort has already survived 0, 1, 3 years) between 1988 and 2010 of pancreatic cancer by stage at diagnosis according to [[SEER]]. These graphs are adapted from [[SEER]]: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | Shown below is an image depicting the 5-year conditional relative survival (probability of surviving in the next 5-years given the cohort has already survived 0, 1, 3 years) between 1988 and 2010 of pancreatic cancer by stage at diagnosis according to [[SEER]]. These graphs are adapted from [[SEER]]: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
<figure-inline class="mw-default-size"><figure-inline><figure-inline>[[Image:Survival time of pancreatic cancer by stage.PNG|646x646px]]</figure-inline></figure-inline></figure-inline> | <figure-inline class="mw-default-size"><figure-inline><figure-inline><figure-inline>[[Image:Survival time of pancreatic cancer by stage.PNG|646x646px]]</figure-inline></figure-inline></figure-inline></figure-inline> | ||
==References== | ==References== | ||
Revision as of 15:08, 15 November 2017
|
Pancreatic cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancreatic cancer natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Pancreatic cancer natural history, complications and prognosis |
|
FDA on Pancreatic cancer natural history, complications and prognosis |
|
CDC on Pancreatic cancer natural history, complications and prognosis |
|
Pancreatic cancer natural history, complications and prognosis in the news |
|
Blogs on Pancreatic cancer natural history, complications and prognosis |
|
Risk calculators and risk factors for Pancreatic cancer natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
The symptoms of pancreatic cancer usually develop in the sixth decade of life, and start with symptoms such as jaundice, light-colored stools, dark urine, pain in the upper or middle abdomen and back, unexplained weight loss, anorexia and fatigue.Symptoms typically develop about 20-30 years after exposure to risk factors such as smoking and alcohol. Genetic factors such as alterations in tumor suppressor genes, oncogenes and different signaling pathways are responsible. If left untreated, patients with pancreatic cancer may progress to develop exocrine pancreatic insufficiency arising from pancreatic duct obstruction leading to malabsorption, malnutrition and cachexia. Dudodenal obstruction and biliary obstruction may cause symptoms of bowel obstruction and jaundice. Common complications of pancreatic cancer may arise as a result of the disease or therapy (surgical or medical). Depending on the extent of the tumor at the time of diagnosis, the prognosis is generally regarded as poor, with complete remission extremely rare.
Natural History, Complications and Prognosis
Natural History
- The symptoms of pancreatic cancer usually develop in the sixth decade of life, and start with symptoms such as jaundice, light-colored stools, dark urine, pain in the upper or middle abdomen and back, unexplained weight loss, anorexia and fatigue.
- The symptoms of pancreatic cancer typically develop about 20-30 years after exposure to risk factors such as smoking and alcohol. Genetic factors such as alterations in tumor suppressor genes, oncogenes and different signaling pathways may also be responsible.
- If left untreated, patients with pancreatic cancer may progress to develop exocrine pancreatic insufficiency arising from pancreatic duct obstruction leading to malabsorption, malnutrition and cachexia. Dudodenal obstruction and biliary obstruction may cause symptoms of bowel obstruction and jaundice.
Complications
- Common complications of pancreatic cancer may arise as a result of the disease or therapy:
Malabsorption:
- Exocrine pancreatic insufficiency due to pancreatic duct obstruction by the tumor may lead to malabsorption. Malabsorption in patients presents with anorexia, weight loss, and diarrhea.
Pain:
- Patients with advanced pancreatic cancer may develop intractable pain requiring narcotic analgesics and surgical intervention such as neurolysis of celiac ganglia.
Jaundice:
- Obstructive jaundice can present with features of cholangitis:
- Fever and chills
- Nausea, vomiting
- Clay-colored stools
- Dark urine
- Yellowish discoloration of skin
- Pruritus
- Right upper quadrant pain
- Anorexia
- Patients may require Endoscopic decompression with stent placement in patients due to biliary obstruction.
Duodenal obstruction
- Patients may develop duodenal obstruction as a result of complications of surgery.
- Duodenal obstruction may be treated with endoscopic stenting or gastrojejunostomy.
Prognosis
- The primary factors that influence prognosis are:
- Whether the tumor is localized and can be completely resected
- Whether the tumor has spread to lymph nodes or elsewhere
- Staging and TNM (tumour, lymph node, metastasis) classification related to incidence, treatment, and prognosis: [1]
| Staging and TNM Classification related to Incidence, Treatment, and Prognosis | ||||
|---|---|---|---|---|
| Stage | TNM Classification | Clinical Classification | Incidence at diagnosis (%) | 5-year survival rate (%) |
| 0 | Tis, N0, M0 | Resectable | 7.5 | 15.2 |
| IA | T1, N0, M0 | — | — | — |
| IB | T2, N0, M0 | — | — | — |
| IIA | T3, N0, M0 | — | — | — |
| IIB | T1-3, N1, M0 | Locally advanced | 29.3 | 6.3 |
| III | T4, any N, M0 | — | — | — |
| IV | Any T, any N, M1 | Metastatic | 47.2 | 1.6 |
5-Year Survival
- For patients with localized disease and small cancers (<2 cm) with no lymph node metastases and no extension beyond the capsule of the pancreas, complete surgical resection is associated with a 5-year survival rate of 18% to 24%.
- Between 2007 and 2010, the 5-year relative survival of patients with pancreatic cancer was 7.2%.[2]
- When stratified by age, the 5-year relative survival of patients with pancreatic cancer was 10% and 4.6% for patients <65 and ≥ 65 years of age respectively.[2]
- The survival of patients with pancreatic cancer varies with the stage of the disease. Shown below is a table depicting the 5-year relative survival by the stage of pancreatic cancer:[2][3]
| Stage | 5-year relative survival (%), (2004-2010) |
| All stages | 6.7% |
| Localized | 25.8% |
| Regional | 9.9% |
| Distant | 2.3% |
| Unstaged | 4.4% |
Shown below is an image depicting the 5-year conditional relative survival (probability of surviving in the next 5-years given the cohort has already survived 0, 1, 3 years) between 1988 and 2010 of pancreatic cancer by stage at diagnosis according to SEER. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[2]
<figure-inline class="mw-default-size"><figure-inline><figure-inline><figure-inline>
</figure-inline></figure-inline></figure-inline></figure-inline>
References
- ↑ Bond-Smith G, Banga N, Hammond TM, Imber CJ (2012). "Pancreatic adenocarcinoma". BMJ. 344: e2476. doi:10.1136/bmj.e2476. PMID 22592847.
- ↑ 2.0 2.1 2.2 2.3 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
- ↑ Ghaneh P, Costello E, Neoptolemos JP (2007). "Biology and management of pancreatic cancer". Gut. 56 (8): 1134–52. doi:10.1136/gut.2006.103333. PMID 17625148.